V1RC3 inhibitors represent a specialized class of chemical compounds aimed at inhibiting the activity of the V1RC3 protein. This class is characterized by its diverse chemical structures, which are meticulously designed to interact with the V1RC3 protein with high specificity. The core chemical features of these inhibitors include various heterocyclic systems, aromatic rings, and functional groups that are carefully chosen to enhance binding affinity and selectivity. These chemical entities are often engineered to fit precisely within the protein's active site or other key interaction regions, thereby disrupting the normal function of V1RC3.
The synthesis of V1RC3 inhibitors typically involves a combination of traditional organic synthesis techniques and advanced methodologies such as computational modeling and high-throughput screening. By leveraging the structural details of V1RC3, chemists can design inhibitors that exhibit optimal interactions with the target protein. This involves the precise arrangement of chemical moieties to form stable, high-affinity complexes with V1RC3. The chemical diversity within this class reflects the ongoing effort to develop compounds with varying binding profiles and functional properties, allowing for the exploration of different mechanisms of inhibition. The sophistication in the chemical design of V1RC3 inhibitors underscores the complexity of tailoring compounds to achieve specific interactions with their target protein, providing insight into the nuanced approach required for effective inhibition.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
A cell-permeable calcium chelator that may indirectly affect V1R11 by altering intracellular calcium levels, which are crucial for signal transduction. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Increases adenylate cyclase activity, raising cAMP levels and potentially modulating signaling pathways associated with V1R receptors. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Serves as a tyrosine kinase inhibitor, potentially impacting V1R11 signaling indirectly by inhibiting downstream signaling pathways. | ||||||
KT 5720 | 108068-98-0 | sc-3538 sc-3538A sc-3538B | 50 µg 100 µg 500 µg | $97.00 $144.00 $648.00 | 47 | |
A PKA inhibitor that might modulate the signaling pathways involved in V1R11 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor, potentially affecting the signaling pathways in which V1R11 participates. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An MEK inhibitor, which could indirectly influence V1R11 activity by affecting MAPK/ERK pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor, potentially altering the signaling pathways associated with V1R11. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
A calmodulin antagonist, which may indirectly affect V1R11 signaling by modulating calcium signaling pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A ROCK inhibitor, potentially affecting cytoskeletal arrangements and indirectly influencing V1R11 signaling. | ||||||